Compare Amylx Pharmaceuticals Inc (AMLX) vs Solaredge Technologies Inc (SEDG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Solaredge Technologies Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.91 (market cap $2.64B), while Solaredge Technologies Inc trades at $32.48 (market cap $2.05B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | SEDG | |
|---|---|---|
Market Cap | $2.64B | $2.05B |
Sector | Health | Technology |
52-Week High | $24.19 | $78.51 |
52-Week Low | $7.82 | $25.10 |
Enterprise Value | $2.39B | $1.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
SolarEdge Technologies (SEDG) trades at $32.21, up 1.42% today, amid a volatile period following its Q2 2026 earnings beat but weak Q3 guidance. The technical outlook is bearish with key support at $30, while fundamentals show revenue of $1.18B in 2025 but a net loss of -$405M, reflecting margin pressures. Analyst sentiment is mixed with a $35.15 consensus target, but recent downgrades highlight execution risks.
The stock faces headwinds from U.S. residential market challenges and policy dependence, though European growth offers some upside. Risks include high debt and persistent losses, but cost controls and storage expansion could support a turnaround if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Solaredge Technologies Inc
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.
Read more on SEDG →
